CHRISTABEL LARTEY: Open Payments
NPI 1962762237 · MANASSAS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,917 in 73 payments from 11 companies in 2025. Trend: 2023 $2,080 · 2024 $2,746 · 2025 $1,917
Food & beverage: $1,917
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $389 |
| ABBVIE INC. | 15 | $302 |
| Otsuka America Pharmaceutical, Inc. | 7 | $280 |
| E.R. Squibb & Sons, L.L.C. | 11 | $227 |
| Janssen Pharmaceuticals, Inc | 6 | $187 |
| Vanda Pharmaceuticals Inc. | 5 | $131 |
| Braeburn Inc. | 1 | $109 |
| Neurocrine BioSciences, Inc. | 4 | $97 |
| Lundbeck LLC | 5 | $95 |
| Teva Pharmaceuticals USA, Inc. | 3 | $69 |
Products named: VRAYLAR, ARISTADA, COBENFY, ABILIFY ASIMTUFII, INVEGA SUSTENNA, REXULTI, LYBALVI, FANAPT.
Industry payments across VA — which companies pay providers there.
